What is Invokana?
Invokana (canagliflozin) is a medication used to treat type 2 diabetes. It was initially approved by the U.S. Food and Drug Administration (FDA) in 2013. Invokana works by blocking a protein in the kidneys, which can help reduce blood sugar levels by causing the body to excrete more glucose in urine.
However, Invokana also has some side effects, including the risk of lower limb amputations, urinary tract infections, and diabetic ketoacidosis (a serious complication of diabetes). The risk of lower limb amputations was confirmed by the FDA in 2018 following reports of increased cases of leg and foot amputations in individuals taking Invokana. Other side effects may include dehydration, dizziness, and nausea.
It is important to consult with a healthcare provider before taking Invokana, especially if a person has a history of kidney problems, has had a previous amputation, or is taking other medications that may interact with Invokana. Additionally, Invokana should not be used in individuals with type 1 diabetes or diabetic ketoacidosis.
In conclusion, Invokana can be an effective medication for treating type 2 diabetes, but it is not without risks and potential side effects. It is important to discuss the risks and benefits of taking Invokana with a healthcare provider, and to closely monitor for any adverse effects while taking the medication.
Frequently Asked Questions about invokana
INVOKANA® (canagliflozin) is a prescription medicine used: along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes. to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who have known cardiovascular disease.
Invokana (canagliflozin) is a Type 2 diabetes medicine. It belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. Some of the rare, but characteristic side effects of Invokana include amputations, diabetic ketoacidosis (too much acid in the blood) and kidney injury.
In most clinical studies, INVOKANA® has helped people with type 2 diabetes reach the ADA-recommended blood sugar (A1C) goal of less than 7%.
Canagliflozin is an SGLT-2 inhibitor that increases glucose excretion in the urine by reducing re-absorption of filtered glucose and lowering the renal glucose threshold.
On May 18, 2016, FDA issued a Drug Safety Communication warning the public about interim safety results from “an ongoing clinical trial that found an increase in leg and foot amputations, mostly affecting the toes,” in patients who had taken Invokana.
No, Invokana is not the same medicine as metformin. Invokana and metformin both are medicines that treat type 2 diabetes by lowering blood glucose levels, but they work in different ways.
The Invokana court proceedings were known as the Invokana Multi-District Ligitation. Plaintiffs claimed that Invokana caused them to suffer amputations, kidney damage, and/or ketoacidosis. Yet, the makers of Invokana failed to warn doctors and patients of these potential side effects.
Invokana (canagliflozin) is a medication used to treat Type 2 diabetes. Its most common side effects include genital and urinary infections. Other possible Invokana side effects include low blood pressure and low blood sugar. Serious Invokana side effects include lower limb amputation, ketoacidosis, and bone fractures.
Taking Invokana can increase your risk of kidney damage. Symptoms of kidney damage can include: urinating less often than normal. swelling in your legs, ankles, or feet.
Invokana remains on the market, with reports to the FDA of ketoacidosis and related events linked to the drug now numbering in the thousands. However, sales have declined as the drug's label has been laden with warnings about ketoacidosis and other possible adverse effects.
Multiple brand-name medications are similar to Invokana. Farxiga (dapagliflozin) and Jardiance (empagliflozin) are two SGLT2 inhibitors used to control blood sugar in those with Type 2 diabetes. Both of these have been shown to lower A1C levels.
Although they belong to the same class of drugs, JARDIANCE® and INVOKANA® are two different things. The generic name of JARDIANCE® is empagliflozin, and the generic name of INVOKANA® is canagliflozin. INVOKANA® can elevate your risk of lower leg amputation.
